Overview
McDermott Will & Emery has advised Crédit Mutuel Innovation on the Series C financing of UroMems, an international company developing an innovative, implantable mechatronic technology to treat stress urinary incontinence (SUI).
The round, totaling around €44 million, was led by Crédit Mutuel Innovation and joined by the European Innovation Council, as well as existing investors Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners and Financière Arbevel.
This Series C financing will enable UroMems to fund pivotal clinical trials of the UroActive™ system, the first intelligent automated implant to treat stress urinary incontinence.
This is the largest fundraising to date for UroMems.
The McDermott team advising Crédit Mutuel Innovation comprised:
- Anthony Paronneau, partner, Lucie Martin and Ludivine Rabreau, associates (Corporate)
- Antoine Vergnat, partner, and Oriane Beauvois, associate (Tax)
- Naré Arshakyan, associate (Social)
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
